279692-23-8

Basic information

• Product Name: Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate
• Synonyms: Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate
• CAS NO: 279692-23-8
• Molecular Formula: C₁₆H₁₉NO₄
• Molecular Weight: 289.329
• Product Categories: Phenyls & Phenyl-Het;Esters;Phenyls & Phenyl-Het
• Mol File: 279692-23-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 149～151℃
• Boiling Point: 488.7°C at 760 mmHg
• Flash Point: 249.4°C
• Appearance: /
• Density: 1.168g/cm³
• Vapor Pressure: 1.06E-09mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: 2-8°C
• PKA: -2.96±0.40(Predicted)
• CAS DataBase Reference: Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate(279692-23-8)
• EPA Substance Registry System: Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate(279692-23-8)

Safety Data

• Hazardous Substances Data: 279692-23-8(Hazardous Substances Data)

Usage

General Description

Ethyl 4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)benzoate is a chemical compound with the molecular formula C18H23NO4. It is commonly used as an intermediate or building block in the synthesis of pharmaceutical drugs and other organic compounds. The compound is a derivative of benzoic acid and contains a piperidine ring, making it useful in the development of various pharmaceuticals and agrochemicals. It is a white to off-white solid with a molecular weight of 317.38 g/mol. The compound is typically synthesized through multi-step organic reactions and purification processes. It is important for researchers and chemists in the pharmaceutical and chemical industries due to its potential applications in drug development and other organic syntheses.

InChI:InChI=1/C16H19NO4/c1-4-21-15(20)11-5-7-12(8-6-11)17-13(18)9-16(2,3)10-14(17)19/h5-8H,4,9-10H2,1-3H3

Upstream product

• 1131-15-3 2-phenylsuccinic anhydride 
• 17347-61-4 2,2-dimethylsuccinic anhydride 
• 619-45-4 4-methoxycarbonyl aniline 
• 108-30-5 succinic acid anhydride 
• 75-36-5 acetyl chloride 
• 94-09-7 p-aminoethylbenzoate 
• 314256-16-1 3,3-dimethylglutaric anhydride 
• 5617-74-3 3-oxabicyclo[3.1.0]hexane-2,4-dione 
• 4160-82-1 3,3-dimethylglutaric anhydride 
• 279692-22-7 4-(4-carboxy-3,3-dimethyl-butyrylamino)-benzoic acid ethyl ester 
• 2938-48-9 2,2-dimethylglutaric anhydride 

Downstream Products

• 406233-25-8 ethyl 4-(4,4-dimethylpiperidin-1-yl)benzoate 
• 406233-26-9 4-(4,4-dimethylpiperidin-1-yl)benzoic acid 
• 406231-90-1 N-[4-(4,4-dimethyl-piperidin-1-yl)-benzoyl]-3-nitro-4-(2-phenylsulfanyl-ethylamino)-benzenesulfonamide 
• 406228-55-5 (R)-4-(3-dimethylamino-1-phenylsulfanylmethylpropylamino)-N-[4-(4,4-dimethylpiperidin-1-yl)benzoyl]-3-nitrobenzenesulfonamide 
• 406228-55-5 4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-[4-(4,4-dimethyl-piperidin-1-yl)-benzoyl]-3-nitro-benzenesulfonamide 
• 406229-95-6 (5-{4-[4-(4,4-dimethyl-piperidin-1-yl)-benzoylsulfamoyl]-2-nitro-phenylamino}-6-phenylsulfanyl-hexyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo

Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-XL function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-μM binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-XL binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-XL with a Ki of 0.8 μM. In a cellular assay 73R reversed the protection afforded by Bcl-XL overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 μM. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.

N-Acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula Are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.